ALT vs JNJ · rev $5.0K vs P/E 17, rev $49.37B
Altimmune Inc (ALT) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Altimmune Inc (ALT) is a biotechnology company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported ALT revenue for 2025-09-30 was $5.0K. Net income was -$60.7M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. ALT currently screens at market cap $527.0M.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
ALT currently screens at market cap $527.0M. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the ALT and JNJ stock pages for the full models.
Not investment advice.